StockData

Longeveron vs Cartesian Therapeutics

LGVN and RNAC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LGVN and RNAC compare

Cartesian Therapeutics is the larger company, worth 2.7 times as much as Longeveron ($184M against $67.3M).

Longeveron keeps more of each dollar of sales as profit, with a net margin of −1978% compared with −10284% at Cartesian Therapeutics.

Longeveron scores higher on the StockData Score (5 against 1 for Cartesian Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLGVNRNAC
Size and price
Market cap$67.3M$184M
Share price$2.11$6.08
Change, 1 year−69.0%−15.9%
Change, 5 years−99.9%−93.0%
Beta (5Y)1.442.27
Employees3775
StockData Score
Total score5 (better)1
Valuation score00
Growth score00
Performance score00
Health score5 (better)1
Dividend score00
Valuation
P/S56.7× (better)125×
P/B6.5×–
FCF yield−30.5% (better)−42.7%
Growth
Revenue growth (TTM)−42.7%–
Revenue growth, 5Y average−26.6% (better)−30.0%
Profitability
Gross margin69.8%–
Operating margin−1993% (better)−10519%
Net margin−1978% (better)−10284%
FCF margin−1730% (better)−5322%
Return on equity−204%–
Return on invested capital−1412%–
Financial health
Debt / equity0.00–
Current ratio2.637.48 (better)
Altman Z-score−9.42−4.57 (better)
Piotroski F-score12 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions1.5%29.3%
Held by insiders43.8%55.7%
Insider net buying, 12 months–−$52.9K
Short interest, % of float0.88%14.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.